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OBJECTIVE—As data on the predictive characteristics of dia-
betes-associated autoantibodies for type 1 diabetes in the general
population are scarce, we assessed the predictive performance
of islet cell autoantibodies (ICAs) in combination with autoanti-
bodies against insulin (IAAs), autoantibodies against GAD,
and/or islet antigen 2 for type 1 diabetes in children with
HLA-deﬁned disease predisposition recruited from the general
population.
RESEARCH DESIGN AND METHODS—We observed 7,410
children from birth (median 9.2 years) for -cell autoimmunity
and diabetes. If a child developed ICA positivity or diabetes, the
three other antibodies were measured in all samples available
from that individual. Persistent autoantibody positivity was de-
ﬁned as continued positivity in at least two sequential samples
including the last available sample.
RESULTS—Pre-diabetic ICA positivity was observed in 1,173
subjects (15.8%), 155 of whom developed type 1 diabetes. With
ICA screening, 86% of 180 progressors (median age at diagnosis
5.0 years) were identiﬁed. Positivity for four antibodies was
associated with the highest disease sensitivity (54.4%) and nega-
tive predictive values (98.3%) and the lowest negative likelihood
ratio (0.5). The combination of persistent ICA and IAA positivity
resulted in the highest positive predictive value (91.7%), positive
likelihood ratio (441.8), cumulative disease risk (100%), and
speciﬁcity (100%). Young age at seroconversion, high ICA level,
multipositivity, and persistent positivity for IAA were signiﬁcant
risk markers for type 1 diabetes.
CONCLUSIONS—Within the general population, the combina-
tion of HLA and autoantibody screening resulted in disease risks
that are likely to be as high as those reported among autoanti-
body-positive siblings of children with type 1 diabetes. Diabetes
58:2835–2842, 2009
T
ype 1 diabetes is an immune-mediated disease
that leads to the destruction of the pancreatic
-cells and eventually to total dependence on
exogenous insulin. The clinical manifestation of
the disease is preceded by a preclinical phase, during
which diabetes-associated autoantibodies (DAAs) can be
detected in the peripheral circulation. The timing and the
type of autoantibodies to appear have been used as
predictive markers for type 1 diabetes among ﬁrst-degree
relatives of affected individuals (1), but data on the pre-
dictive value of DAAs in the background population, from
whom 90% of new cases are derived, are scarce (2).
Today, type 1 diabetes is one of the most common
severe chronic ailments of children and adolescents in
developed countries (3–5), and its incidence is continu-
ously increasing. In Finland, the incidence is highest in the
world, reaching 64 new cases per 100,000 children ages
15 years in 2005 (6). In 1994, a birth cohort study aimed
at predicting and preventing type 1 diabetes in the general
population was launched. The current work represents
data from the ﬁrst 14 years of this study, assessing the
predictive characteristics of DAAs in a population-derived
cohort of children with HLA-conferred susceptibility to
type 1 diabetes.
RESEARCH DESIGN AND METHODS
The Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study was
carried out in three university hospitals (Turku, Oulu, and Tampere). More
than 90% of the 11,000 babies born annually in these centers take part in cord
blood screening for type 1 diabetes–associated HLA genotypes (7). Infants
carrying the high-risk genotype (HLA DQB1*02/0302) or the moderate-risk
genotypes (HLA DQB1*0302/x; x*02, *0301, *0602, or *0603) are eligible for
a prospective follow-up study in which participants are monitored for the
appearance of DAAs and type 1 diabetes (supplementary Fig. 1 [available
at http://diabetes.diabetesjournals.org/cgi/content/full/db08-1305/DC1]) (8,9).
Information on the family history of type 1 diabetes is collected with
structured questionnaires completed by the parents soon after the birth of the
baby. In the study centers in Oulu and Tampere, the clinical follow-up visits
take place at the age of 3, 6, 12, 18, and 24 months and, after that, annually. In
Turku, the visits occur every 3 months until the age of 2 years and
subsequently every 6 months, which makes it theoretically possible that
children from Turku could seroconvert at a younger age than other DIPP
children, but according to current analyses this was not the case. For the
seroconverted subjects, the follow-up visits are organized every 3 months.
At the follow-up visits, venous blood samples are obtained, and for the
current analyses, ICAs were used as the primary screening tool for -cell
autoimmunity. Subjects with transplacentally transferred maternal antibodies
were regarded as seronegative as long as no de novo synthesis of antibodies
was observed (10). Persistent autoantibody positivity (preﬁx “p”) was deﬁned
as positivity in at least two sequential samples, the last sample available being
positive. The last pre-diabetic and/or the ﬁrst diabetic samples were taken into
account when deﬁning the persistence of the autoantibody status. Participants
with persistent positivity for at least two of the autoantibodies analyzed were
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trial with nasally administrated insulin. Codes for the intervention treatment
were opened in November 2007, and the results showed that the intervention
had no effect on the progression rate to clinical diabetes (11). The present
study cohort comprised DIPP children who had remained in the follow-up
study for at least 1 year or presented with diabetes before the age of 1 year
(one case diagnosed at the age of 0.9 years) by the end of August 2004. The
cohort included 7,410 children (3,897 male subjects [52.6%]), and 177 (2.4%)
had a family member affected by type 1 diabetes at the time of birth. The
closing time point for the data on autoantibodies and progression to type 1
diabetes was 31 December 2008.
Screening for HLA DQB1 genotypes was performed on cord blood samples
by time-resolved triple-label hybridization (12). Autoantibodies were mea-
sured on serum samples: islet cell autoantibodies (ICAs) with immunoﬂuo-
rescence (13) and antibodies against insulin (IAAs), antibodies against GAD
(GADAs), and islet antigen 2 (IA-2A) with speciﬁc radiobinding assays
(14–16). The cut-off values for ICA, IAA, GADA, and IA-2A positivity were 2.5
Juvenile Diabetes Foundation units (JDFU), 3.48 relative units (RU), 14.13
World Health Organization (WHO) units/ml ( 5.36 RU), and 1.91 WHO
units/ml ( 0.43 RU), respectively. The reference values for the IAA, GADA,
and IA-2A assays were based on the 99th percentile of 370 nondiabetic
Finnish children and adolescents. Samples with IAA, GADA, or IA-2A values
between the 97th and 99.5th percentiles, as well as all the ICA-positive
samples, were retested to conﬁrm the antibody status. The disease sensitivity
and speciﬁcity of the ICA assay were 100 and 98%, respectively, based on an
international standardization workshop round (17). According to the 2005
Diabetes Autoantibody Standardization Program (DASP) workshop, the dis-
ease sensitivity of the IAA, GADA, and IA-2A assays were 58, 82, and 72%,
respectively, while corresponding speciﬁcities were 98, 96, and 100%, respec-
tively. The diagnosis of type 1 diabetes was based on WHO criteria (18) and
the primary case ascertainment done by reviewing the local registers of
children with newly diagnosed type 1 diabetes in each of the three participat-
ing university hospitals. The Finnish Pediatric Diabetes Register was used as
the secondary source of ascertainment (19). The local ethics committees
approved the protocol of the DIPP study, and written informed consent was
obtained from the legal representatives of the participating children.
Data analysis. To analyze the predictive characteristics of ICA-based auto-
antibody combinations, participants were categorized by their maximal auto-
antibody status by the end of December 2008. Each child could belong to one
group only, except when the categories “two or more” and “three or more”
DAAs were analyzed. For subjects with ﬂuctuating autoantibodies, the maxi-
mal combination or, in the case of various combinations with similar numbers
of positive autoantibodies, the ﬁrst combination to appear was chosen.
Disease sensitivity and speciﬁcity, as well as positive (PPV) and negative
(NPV) predictive values and likelihood ratios (LR and LR), were deter-
mined for ICA alone and for ICA in combination with the other three
autoantibodies. The Kaplan-Meier method with the log-rank test was used to
analyze and compare the cumulative diabetes risks. Odds ratios (ORs) for the
risk of type 1 diabetes were calculated. Distributions between groups were
tested with the 	
2 test and correlations analyzed with the Pearson’s (r)o r
Spearman’s methods (rs). CIs were given at 95% (95% CI), and statistical
signiﬁcance was set at P  0.05 (two-tailed). Statistical analyses were
performed with SPSS 16.0 for Windows (SPSS, Chicago, IL).
RESULTS
We observed from birth 7,410 children for positivity for
DAAs and progression to type 1 diabetes over a median
follow-up time of 9.2 years (range 0.9–14.2). The median
follow-up time for subjects remaining unaffected by type 1
diabetes was 9.3 years (5.4–14.2), and the median age at
diagnosis among 180 progressors (93 male subjects [2.4%])
was 5.0 years (0.9–12.5). The median age at the initial
seroconversion was 4.2 years (0.2–13.7) among unaffected
ICA-positive subjects, whereas among progressors, it was
1.5 years (0.3–9.6; P  0.001). Progressors reached the
maximal ICA-based autoantibody status by the median age
of 2.2 years (0.5–10.1), while in unaffected subjects, the
maximal autoantibody status was observed at the age of
5.1 years (0.5–13.7; P  0.001). Delay from the initial
seroconversion to maximal autoantibody positivity varied
between 0.0 and 11.0 years, and among progressors and
unaffected subjects, the median delays were 0.5 and 0.0
years (P  0.001), respectively. The high-risk genotype
(DQB1*02/0302) was carried by 1,575 children (21.3%) and
the moderate-risk genotypes (DQB1*0302/x; x  *02 or a
protective allele) by 5,835 children (78.7%). The high-risk
genotype was associated with higher risks for developing
-cell autoimmunity, positivity for multiple autoantibod-
ies, persistent positivity, and type 1 diabetes (P  0.001 for
all comparisons) (supplementary Table 1). The corre-
sponding ORs for the high- versus moderate-risk groups
were 1.7 (95% CI 1.4–2.0), 2.4 (1.9–3.1), 1.7 (1.4–2.0), and
3.2 (2.1–4.8), respectively.
Altogether, 1,173 subjects (15.8%), 155 of whom were
progressors, tested positive for ICAs during the follow-up.
A majority (n  967; 82.4%) of the ﬁrst autoantibody-
positive samples were ICA positive, while positivity for
either ICAs or IAAs was seen in 93.3% (1,094 of 1,173) of
the initially positive samples. Seventeen (68.0%) of 25
progressors who had remained ICA-negative during the
pre-diabetic phase were positive for IAAs either before or
at the time of the diagnosis (Table 1), and, in all, among the
ICA-positive children, those who tested positive also for
IAAs had a higher cumulative disease risk (59.6% [95% CI
49.9–69.3]) than those who remained IAA negative (10.8%
[6.8–14.9]; P  0.001). Twelve of 15 (80%) progressors
without any signs of pre-diabetic -cell autoimmunity did
not adhere to the follow-up schedule of the DIPP study.
Among these subjects, the median delay from the last
sampling to diagnosis was 3.8 years (range 1.9–6.2). All
previously seronegative progressors having samples avail-
able at diagnosis had developed -cell autoimmunity by
that time, and all but one tested positive for multiple
autoantibodies.
The age at which subjects seroconverted had a pre-
dictive role regarding the risk of type 1 diabetes. Among
all ICA-positive subjects, those with seroconversion
before the age of 2 years had the highest cumulative
disease risk (36.9% [95% CI 28.5–45.3]) (Fig. 1A), and for
that age-group, the OR for type 1 diabetes was 5.0 (95%
CI 3.5–7.1) when compared with those who had sero-
converted after the age of 2 years. Subjects seroconvert-
ing under the age of 2 years were also more often
positive for multiple autoantibodies at ﬁrst positive
sampling (18.3 vs. 12.1% in subjects with seroconversion
at or after the age of 2 years, P  0.006). The median
delay from the initial seroconversion to diagnosis was
2.8 years (range 0.02–10.9) among the ICA-positive
progressors, and this delay did not correlate with the
age at seroconversion (rs  0.005, P  0.95).
The median ICA level in the ﬁrst ICA-positive samples
was 5 JDFU (range 3–640) among nonprogressors and 15
JDFU (4–668) (P  0.001) in progressors. The higher the
initial ICA value, the higher the cumulative disease risk
(Fig. 1B). The 5-year progression rate for those with a low
initial ICA level (10 JDFU) was 5.7% (95% CI 3.9–7.5),
while the corresponding values for those with moderate
(10–19 JDFU) and high (20 JDFU) ICA titers were 31.8%
(21.8–41.8) and 61.2% (51.1–71.9), respectively. During the
follow-up, the difference in ICA levels became more prom-
inent between progressors and nonprogressors: the peak
ICA titer among progressors reached 168 JDFU (range
5–2,620), while it remained at 5 JDFU (3–2,620) in nonpro-
gressors (P  0.001). Prospective observations from the
time point at which the maximal ICA level was observed
showed a 5-year cumulative disease risk of 2.3% (95% CI
0.3–4.3) among those with a low ICA (10 JDFU) level at
that time, whereas among those with moderate (10–19
JDFU) and high (20 JDFU) ICA levels, the risk estimates
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between all groups), respectively. The maximal ICA level
correlated clearly with the number of detectable autoan-
tibodies at sampling (rs  0.68, P  0.001), but the
correlation between the ICA titer and type 1 diabetes
remained signiﬁcant, even after correcting for the number
of positive autoantibodies (rs  0.10, P  0.001).
To further analyze the predictive role of ICAs in combi-
nation with the other three autoantibodies, ICA-positive
subjects were categorized by their maximal autoantibody
status. Frequencies and predictive characteristics (sensi-
tivity, speciﬁcity, PPV, NPV, LR, LR, and cumulative
disease risks) of the autoantibody combinations are pre-
sented in Table 2 and Figs. 2 and 3. Positivity for four
TABLE 1
Progressors remaining ICA negative during the pre-diabetic phase
HLA-DQB1
Age (years)
Delay
(years) DAA status
Seroconversion Last visit Diagnosis
Last visit to
diagnosis Pre-diabetic At diagnosis
High risk (*02/*0302)
Female 0.98 0.98 1.34 0.36 IAA ICA, IAA, GADA
Female 1.00 1.40 0.40 Negative ICA, IAA, GADA
Female 0.95 1.51 1.69 0.18 IAA, GADA ICA, IAA, GADA
Female 1.07 3.25 2.18 Negative ICA, IAA, GADA
Female 4.00 4.33 0.33 Negative Sample not available
Female 1.58 5.64 4.06 Negative All four DAA
Female 7.59 11.99 4.40 Negative ICA, GADA, IA-2A
Male 0.96 1.62 0.65 Negative ICA, IAA
Male 2.96 7.70 4.74 Negative ICA, GADA, IA-2A
Male 2.51 8.74 6.23 Negative All four DAA
Moderate risk (*0302/x)
Female 0.50 0.76 0.97 0.21 IAA IAA, GADA
Female 0.77 0.77 1.08 0.31 IAA, GADA All four DAA
Female 0.99 0.99 1.47 0.48 IAA ICA, IAA
Female 0.25 2.13 1.88 Negative ICA, IAA, GADA
Female 0.27 3.06 2.79 Negative All four DAA
Female 2.47 5.96 3.49 Negative All four DAA
Female 3.08 6.40 3.32 Negative ICA, IAA, IA-2A
Female 3.02 6.57 3.55 Negative GADA
Female 4.01 4.01 8.18 4.17 GADA ICA, GADA, IA-2A
Female 0.32 6.24 5.92 Negative ICA
Male 1.12 2.14 4.72 2.58 IAA ICA, IAA, IA-2A
Male 1.02 1.02 5.41 4.39 IAA Sample not available
Male 1.03 7.15 6.12 Negative ICA, IA-2A
Male 2.53 2.53 2.70 0.17 IAA, IA-2A ICA, IAA, IA-2A
Male 0.79 0.79 0.87 0.08 IAA, GADA IAA, GADA
x, nonprotective HLA allele.
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FIG. 1. Effect of the seroconversion age on the diabetes-free survival (A) and progression to type 1 diabetes in relation to initial ICA titer (JDFU)
(B). *P < 0.001; †P  0.003; ‡P  0.006. T1D, type 1 diabetes.
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2838 DIABETES, VOL. 58, DECEMBER 2009 diabetes.diabetesjournals.organtibodies was associated with the highest disease sensi-
tivity (54.4%) and NPV (98.9%) and the lowest LR (0.5).
The combination of persistent ICA and IAA positivity
resulted in the highest PPV (91.7%), LR (441.8), cumula-
tive disease risk (100%), and speciﬁcity (100%). The high-
est cumulative disease risks were associated with IAAs
(Fig. 2B and C), whereas GADA positivity resulted in
signiﬁcantly lower disease risks. Especially, the combina-
tion of ICAs and GADAs resulted in a low progression rate,
thus decreasing also the risk estimate of double positivity.
Transient and persistent ICA positivity had different pre-
dictive characters, since only 1.7% (95% CI 0–4.0) of those
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FIG. 2. Progression to type 1 diabetes (T1D) in relation to number of
positive autoantibodies (A) and combinations of double (B) and triple
(C) positivity further deﬁned. *P < 0.001; †P  0.02; ‡P  0.04.
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diabetes.diabetesjournals.org DIABETES, VOL. 58, DECEMBER 2009 2839with transient ICA-based positivity developed type 1 dia-
betes during follow-up, whereas among those with (at
least) pICA positivity, the proportion was 41.2% (34.1–
48.3) (P  0.001). In the whole study population, the
difference between the seronegative and transiently ICA-
positive subjects remained small but signiﬁcant (0.5% [95%
CI 0.3–0.7] vs. 1.7%) (P  0.008). The pICA-based combi-
nations of multiple persistently positive autoantibodies
had highly variable disease risks, the highest associating
with the combination of pICAs and pIAAs (100%) and the
lowest with pICAs and pGADAs (11.2%). Persistent IAA
positivity seemed to distinguish those with a high disease
risk and rapid progression to type 1 diabetes from those
with a lower disease risk and slower progression rate. In
this population, the pIAA positivity–associated 5-year dis-
ease risk was 70.7% (95% CI 62.2–79.1) compared with that
of 11.9% (8.4–15.4) observed among the ICA-positive sub-
jects lacking pIAA positivity. Since all children had been
observed for at least 5 years, the 5-year predictive charac-
teristics are presented in supplementary Table 2. The
predictive characteristics in relation to HLA genotype are
shown in supplementary Table 3, while the corresponding
characteristics of those 7,077 children who had no affected
ﬁrst-degree relative are presented in supplementary Table 4.
DISCUSSION
The virtues of the present work lie in the extensive series
of children with HLA-conferred diabetes susceptibility
derived from a background population with the highest
incidence of type 1 diabetes in the world, and the fact that
they were observed already from birth for the appearance
of signs of -cell autoimmunity and progression to overt
type 1 diabetes. Because of the Finnish Pediatric Diabetes
Register (19), it was also possible to trace the majority of
progressors that had dropped out from the regular pre-
diabetic follow-up and often to even get a blood sample for
autoantibody analyses at the time of their diagnosis.
Our main limitation was using ICAs as the only primary
screening tool for -cell autoimmunity, thus missing some
ICA-negative subjects with positivity for molecular auto-
antibodies. The rationale for this approach was based on
the knowledge available in 1994 at the initiation phase of
the DIPP study. At that time, ICA represented the autoan-
tibody reactivity with the most robust information on their
predictive value (20,21).
The sensitivity of the current screening program would
have increased from the observed 86% for ICAs to 97%, if
IAAs had been added to the initial screening. This would
have reduced the number of pre-diabetically seronegative
progressors. According to our experience, however, the
main reason for pre-diabetic seronegativity was discontin-
uation of the regular follow-up and, extremely rarely, the
fact that no seroconversion had occurred. In the present
series, there were three progressors having otherwise
clinically obvious type 1 diabetes but no known detectable
autoantibodies at the last follow-up visit 4–8 months
before the diagnosis. Unfortunately, for one of these
individuals, no autoantibody sample was obtained at the
diagnosis of clinical disease, while the other two had
developed at least ICA and IAA positivity by the time of
their diagnosis. Twelve of 15 prediabetically seronegative
subjects had dropped out from the regular follow-up, and
in this group, the shortest delay from the last pre-diabetic
sample to diagnosis was 1.9 years. With this observation in
mind, one might suggest that in any screening program
based on autoantibody detection in young children, the
sampling interval should not exceed 2 years.
In the general childhood population selected for disease
risk–related HLA genotypes, isolated low-level ICA posi-
tivity did not confer a signiﬁcant increase in the disease
risk when compared with autoantibody-negative children,
but the risk of type 1 diabetes associated with this marker
was related to its level as well as with multipositivity.
These ﬁndings are similar to those observed among ﬁrst-
degree relatives of children with type 1 diabetes (22–24).
However, the strong correlation between the ICA titer and
the number of positive molecular autoantibodies indicated
the latter phenomenon to be the true risk marker rather
than the ICA titer. As previously reported among ﬁrst-
degree relatives of patients with type 1 diabetes, we also
observed that the younger the child at the seroconversion,
the higher the risk of presenting with clinical diabetes
during the observation period (25). Part of this ﬁnding may
result from the variation in the follow-up times among the
subjects, since the DIPP study is still ongoing, but accord-
ing to the analysis of diabetes-free survival, the group of
the youngest seroconverters differed from the older ones
already 2 years after the seroconversion (progression rate
9.7 vs. 1.4–3.3% in the older age-groups).
The degree of the variation in sensitivity, PPV, LR, and
cumulative disease risk estimates associated with the
different combinations of multipositivity was conspicu-
ously wide. Sensitivity of the categorized autoantibody
combinations remained mainly modest, except for the
quadruple positivity with a slightly higher value of 54%.
Speciﬁcity was 98% for all other markers except isolated
ICA and pICA positivity, and the NPV values were all
97%. Remarkably high PPV (92%), LR (442), and dis-
ease risk (100%) were associated with the combination of
persistently positive ICAs and IAAs. All persistent autoan-
tibody combinations except the combination of pICAs and
pGADAs had LR values 10, indicating an increased
disease risk (26). The predictive characteristics of the
combined ICA and GADA positivity resembled single ICA
positivity, and since some of the ICA positivity is derived
from GADA reactivity, one may assume that the ﬁndings
regarding this combination may be at least partly ex-
plained by overlapping antibody reactivity.
Observations from the current study conﬁrm that in the
general population the combination of HLA genotyping
and autoantibody detection can provide predictive values
similar to those reported among ﬁrst-degree relatives of
affected patients (27–29). For example, in the Childhood
Diabetes in Finland (DiMe) study (29), among siblings of
children with newly diagnosed type 1 diabetes, positivity
for at least three autoantibodies was associated with a
5-year cumulative risk of 57%, while the corresponding
risk was 62% in the present series. Positivity for multiple
autoantibodies is, however, probably less frequent in the
background population than among family members, even
after screening for individuals with HLA-conferred disease
susceptibility. In this study, the frequency of positivity for
three or more DAAs was 3.5% (263 of 7,410), while the
corresponding ﬁgure for DiMe siblings was 4.6%. Accord-
ingly, to identify similar numbers of individuals at high risk
(50% over 5 years) of disease progression from the
background population with HLA-deﬁned diabetes suscep-
tibility, and from siblings of affected children, one-third
more children should be screened from the background
population. Nevertheless, persistently multipositive chil-
dren in the general population represent the majority of
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tive measures covering this part of the population, only a
minor proportion of future cases can be prevented. Given
that the natural progression rate is extremely high in this
group of children, especially among those developing
persistent positivity for IAAs, these children might repre-
sent a subgroup in which more aggressive preventive
treatments may be justiﬁed in the future. Altogether, our
experience shows that it is feasible to observe children
with HLA-deﬁned diabetes susceptibility from birth and to
identify individuals developing -cell autoimmunity among
them. As soon as effective preventive treatments are
available, prevention programs based on HLA genotyping
and regular autoantibody analyses may well be relevant in
high-incidence countries, such as Finland.
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